• Explore /
  • Poster
  • / A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.

A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.

Abstract Video & Slides Poster

Authors

null

Debashis Sarker

King's College London, London, United Kingdom

Debashis Sarker , Udai Banerji , Sarah Patricia Blagden , Natalie Cook , T.R. Jeffry Evans , Elizabeth Ruth Plummer , Marina Braun , Ann Cleverly , Nieves Diaz , Paul Jones , Ivan Matthews , Sophie Glatt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04393298

DOI

10.1200/JCO.2022.40.4_suppl.TPS221

Abstract #

TPS221

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Yelena Y. Janjigian

First Author: Takako Yoshii

First Author: Iwona A. Lugowska

First Author: Meredith Pelster